

FDA-Approved Injectable Disease-Modifying Therapies for MS and the Recommended Laboratory Tests for Pretreatment Testing and Treatment Monitoring

Detailed prescribing information can be found on the FDA's website at: accessdata.fda.gov/scripts/cder/daf/index.cfm.

Medication	Pretreatment Testing	Recommended Laboratory Monitoring
Avonex (interferon beta-1a)	CBC, CMP	CBC with differential (every 6-12 mos) Liver function tests (every 6-12 mos) Thyroid function tests (annually)
Betaseron (interferon beta-1b)	CBC, CMP	CBC with differential (at 1, 3, and 6 mos initially, then every 6-12 mos) Liver function tests (at 1, 3, and 6 mos initially, then every 6-12 mos)
Copaxone (glatiramer acetate)	None	Liver function tests (if clinically indicated)
Extavia (interferon beta-1b)	CBC, CMP	CBC with differential (at 1, 3, and 6 mos initially, then every 6-12 mos) Liver function tests (at 1, 3, and 6 mos initially, then every 6-12 mos)
Glatiramer acetate injection	None	Liver function tests (if clinically indicated)
Glatopa (glatiramer acetate)	None	Liver function tests (if clinically indicated)
Kesimpta (ofatumumab)	HBsAg ^a HBV core antibodies (total) Quantitative serum immunoglobulins	Quantitative serum immunoglobulins (before initiating treatment, every 6-12 mos while receiving treatment, and every 6-12 mos after treatment cessation until immunoglobulin levels normalize)
Plegridy (peginterferon beta-1a)	CBC, CMP	Liver function tests (every 6-12 mos) CBC with differential (every 6-12 mos)
Rebif (interferon beta-1a)	CBC, CMP	CBC with differential (at 1, 3, and 6 mos initially, then every 6-12 mos) Liver function tests (at 1, 3, and 6 mos initially, then every 6-12 mos) Thyroid function tests ^b (every 6 mos)

^aAdditional HBV markers may be included as appropriate per local health department guidelines.

^bThyroid testing is only recommended for patients with a history of thyroid dysfunction or when clinically indicated.

CMP, comprehensive metabolic panel; FDA, U.S. Food and Drug Administration; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; MS, multiple sclerosis

Source: U.S. Department of Health and Human Services, U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs. [Updated: Mar 2018; Accessed: Dec 2022]